Analytics

IQVIA Alternatives: Which Vendor Replaces Which IQVIA Product in 2026

IQVIA alternatives mapped product by product: Xponent, LAAD, OneKey, DDD and CRM, with published figures, switching costs and a test to run before renewal.

Nov 202614 min readAnalytics

IQVIA alternatives: the short answer

The best IQVIA alternatives depend on which IQVIA product you want to replace, because IQVIA is not one product. For prescriber-level prescription data (Xponent and the National Prescription Audit), the realistic alternatives are Veeva Compass and Symphony Health, now owned by HealthVerity. For patient-level claims (LAAD), look at Komodo Health, Veeva Compass Patient and HealthVerity. For HCP reference data (OneKey), the main alternative is Veeva OpenData, with H1 and Definitive Healthcare covering expertise and account intelligence. For analytics services, specialist consultancies and in-house teams replace IQVIA's services arm.

Most directory lists of IQVIA competitors mix clinical research organisations, HCP email list sellers and spreadsheet tools into one ranking, which is no help to a commercial operations lead facing a data renewal. This guide maps each IQVIA commercial product to its alternatives, puts the vendors' own published figures side by side, explains what switching actually costs (usually identifiers and incentive compensation, not the licence), and gives you a parallel test to run before you sign anything.

It is written for commercial operations, sales operations, analytics and finance leads at mid-sized and emerging pharma and biotech companies in the US, especially teams approaching an IQVIA renewal or making a first data purchase ahead of launch.

IQVIA is five purchases, so there are five sets of alternatives

Since 1 January 2026 IQVIA reports two segments: Commercial Solutions and Research and Development Solutions. Its third-quarter 2026 results, released on 27 October 2026, put Commercial Solutions revenue at $1,789 million (up 6.9 percent year on year) and R&D Solutions at $2,639 million, out of $4,428 million in total. If you searched for IQVIA alternatives because you run clinical trials, the alternatives are other CROs. This guide is about the commercial side, which most pharma companies buy as several separate contracts.

What you license from IQVIAWhat it is used forMain alternatives
Xponent and National Prescription Audit (NPA)Prescriber and national prescription volume, share, targeting, incentive compensationVeeva Compass Prescriber and Compass National; Symphony Health PrescriberSource and Metys (HealthVerity)
LAAD and LAAD PlusPatient journeys, switching, persistence, patient findingKomodo Health Healthcare Map; Veeva Compass Patient; HealthVerity and Symphony PatientSource
OneKeyHCP and HCO reference data behind CRM, targeting and complianceVeeva OpenData; H1 for expertise profiles; Definitive Healthcare for hospital, IDN and physician group intelligence
DDD (outlet-level sales)Non-retail and institutional sales by accountYour own distributor 867 and specialty pharmacy 852 and 867 feeds, collected directly or through a data aggregator
OCE CRM, analytics and servicesField engagement, dashboards, targeting models, sales operations supportVeeva Vault CRM or Salesforce Life Sciences Cloud; AI targeting software such as ODAIA; specialist analytics consultancies or an in-house team

The practical point: you can replace one row and keep the rest. Many brands keep Xponent for incentive compensation and move patient work to another vendor, or keep OneKey and switch CRM. Since IQVIA and Veeva settled their litigation on 18 August 2025 and signed third-party access agreements, IQVIA data can be used in Veeva Network, Veeva Nitro and Veeva AI, and Veeva data in IQVIA software, so a mixed set-up is now a normal configuration rather than a fight.

The main IQVIA competitors for commercial data

  • Veeva Compass

    Veeva's US commercial data suite: Compass Patient, Compass Prescriber and Compass National. It is the closest like-for-like replacement for Xponent, NPA and LAAD from a single vendor, sold with unlimited use per subscribed brand.

    • Retail and non-retail in one view
    • Joins to Veeva OpenData on Veeva IDs
    • US only
  • Komodo Health

    A US patient data company built around its Healthcare Map, which links de-identified patient journeys from more than 60 open and closed claims sources and refreshes daily. Usually bought for pathway, switching and patient finding work rather than sales crediting.

    • Daily refresh
    • Snowflake Marketplace delivery since October 2025
    • Not a projected Rx audit
  • HealthVerity and Symphony Health

    HealthVerity completed its purchase of Symphony Health from ICON on 8 May 2026, combining Symphony's prescriber-level Rx data with HealthVerity's patient identity and real-world data exchange. The long-standing challenger to Xponent, and a useful lever in any renewal.

    • PrescriberSource, PatientSource, Metys
    • Linked Rx, claims and EMR under one owner
    • Ask about identifier continuity
  • Veeva OpenData

    HCP and HCO reference data that competes directly with OneKey. The default for companies on Vault CRM or Veeva Network, with built-in change request handling and US coverage at a similar scale to OneKey.

    • Natural fit with Vault CRM
    • Separate email product
    • Coverage outside the US by country
  • H1

    An HCP intelligence platform that profiles doctors through publications, trials, congresses, payments and claims. Strong for KOL identification, medical affairs and specialist targeting; it complements rather than replaces a prescription audit.

    • Expertise-led profiles
    • Prescriber Universe for commercial use
    • Data feeds into your own platforms
  • Definitive Healthcare

    Provider and organisation intelligence: hospital, IDN and physician group profiles, affiliations and claims-based activity. Commercial teams use it for account-based targeting and market access, rarely as a replacement for prescription data.

    • Account and IDN focus
    • Useful beside OneKey or OpenData
    • Test HCO matches on your accounts

IQVIA vs alternatives by the numbers

These are each vendor's own published figures, collected for our individual comparisons between October and November 2026: IQVIA's Xponent fact sheet (2024), OneKey US fact sheet (March 2025) and LAAD Plus page; Veeva's Compass and OpenData US pages; Komodo Health's Healthcare Map page; and HealthVerity's May 2026 acquisition announcement plus ICON's earlier Symphony page. None of these vendors publishes list prices.

MeasureIQVIAClosest alternative
Prescriber-level Rx coverageXponent: 93% of retail, 77% of mail order, 74% of long-term care prescriptionsSymphony IDV: 85% retail and 72% mail (ICON-era); 90% retail for the combined HealthVerity company. Veeva Compass Prescriber: top 4,000 brands, retail and non-retail, 2 million+ HCPs
Patient-level claimsLAAD Plus: 400 million+ de-identified patientsKomodo Healthcare Map: 330 million+ patients, refreshed daily. Compass Patient: 300 million+ patients, 8+ years of history
HCP reference data (US)OneKey: 11.3 million HCPs, 746,211 HCOsVeeva OpenData: 12 million HCPs, 2 million HCOs
Expertise dataNot the focus of OneKeyH1: 12 million+ HCP profiles globally, 120 million+ publications
LicensingPer product and use; third-party access under IQVIA termsCompass: unlimited use for each subscribed brand. Others: quote-based
GeographyUS plus many other countriesCompass, Komodo and Symphony are US data; OpenData covers many countries, checked market by market

Do not rank vendors on these rows. Each one counts patients, prescribers and organisations differently, and a coverage percentage tells you how much a vendor sees before estimation, not how accurate its estimate is for your product. Two million HCOs against 746,211 reflects different definitions of an organisation as much as better coverage. The only number that settles a choice is a test on your own market, described below. For the full detail behind each row, see our head-to-head guides: Veeva Compass vs IQVIA, Symphony Health vs IQVIA, Komodo Health vs IQVIA, Veeva OpenData vs IQVIA OneKey and H1 vs IQVIA.

Which IQVIA alternative fits your situation?

Emerging biotech

You may not need a full audit stack. If the product moves through a limited specialty pharmacy network, your own specialty pharmacy and hub data answers most operational questions, with patient claims from Komodo, Compass Patient or HealthVerity added for competitor and switching analysis. Buy prescriber-level Rx data when you have a field team whose pay depends on it.

Incentive pay on Xponent

Switching the crediting source is the most expensive change you can make, because every territory number moves. If the reason for change is price or flexibility, run Compass Prescriber or Symphony in parallel for at least a full quarter and switch only at a plan year boundary, or use the results to renegotiate.

Patient journeys

This is where alternatives are most mature. Komodo, Compass Patient and HealthVerity all sell linked, de-identified patient data. Send each the same written market definition and compare patient counts, refresh lag and continuous enrollment on your indication.

Global brand

Most challengers are US-only. IQVIA remains the vendor with prescription data in many countries, so a common set-up is IQVIA outside the US and a US alternative for patient-level work, both landing in one warehouse with shared definitions.

What switching away from IQVIA really costs

Buyers usually compare licence quotes. The larger costs sit elsewhere, and they are the reason many companies that shop for IQVIA alternatives end up renewing at a better price instead of switching.

  • Identifiers. IQVIA data is keyed to OneKey IDs; Compass joins to Veeva IDs; other vendors bring their own. Every call history, territory alignment, segmentation table and warehouse join that uses the old key must be remapped through NPI and a crosswalk. If your CRM runs on one reference set, the data product that shares its identifiers is cheaper to integrate. Our guide to HCO hierarchy in pharma covers the account side of this.
  • Incentive compensation. Projected prescriber data from two vendors can agree nationally within a few percent and still differ widely by territory. That difference is someone's bonus. Plan the change with your incentive compensation rules, not after them.
  • History. Trend lines, deciles and forecasts need restated history from the new vendor. Confirm how many years each product includes and whether it is restated when late data arrives.
  • Permitted use. Licences decide which agencies and consultants may touch the data, whether prescriber-level output can go to the field, and what happens to derived tables when you leave. The 2025 settlement made third-party access easier, not automatic.
  • Parallel running. For a quarter or more you pay for two sources and the analyst time to reconcile them. Budget it explicitly.

None of this is a reason to stay put. It is a reason to price the whole move, not the licence, and to use a credible alternative as leverage even if you renew.

How to evaluate IQVIA alternatives before you sign

List what you license and why

Write down every IQVIA product, which teams use it, which reports and payouts depend on it, and its renewal date. Most companies find at least one feed nobody uses and one that cannot change without breaking incentive pay.

Write one market definition

Agree the products, NDCs, diagnosis and procedure codes, specialties and time window that define your market. Send the same document to IQVIA and every alternative so the answers are comparable.

Request feasibility counts

Under NDA, ask each vendor for prescriber and patient counts by quarter, region, channel and payer type, plus HCP and HCO match rates against a sample of your own target list.

Check against data you trust

Compare the counts with your specialty pharmacy shipments, distributor 867 sales and hub enrollments. The vendor whose differences you can explain is usually the safer choice.

Run a parallel quarter

Load the shortlisted source next to your current one and rebuild territory volume, deciles and a mock payout. Measure how many territories move by more than your tolerance, and why.

Map the integration and price the move

Count the crosswalks, pipelines and report changes needed, add parallel running and analyst time, then negotiate the term with test results in hand. Write lag, refresh and restatement commitments into the contract.

A worked example: an IQVIA renewal for a 40-rep brand

The figures below are illustrative, chosen to show how the decision usually plays out rather than taken from any client. A mid-sized specialty company has one growing brand, 40 field reps and a three-year IQVIA contract for Xponent, LAAD and OneKey coming up for renewal in six months. Finance wants the data budget cut. Brand wants daily patient data. Sales operations wants nothing that breaks the incentive plan.

  • Inventory. The team finds that LAAD is used by one analyst for quarterly pathway slides, OneKey feeds the CRM and the warehouse, and Xponent drives goals and payouts for all 40 territories.
  • Feasibility. Komodo and Compass Patient both return patient counts the team can explain against its specialty pharmacy shipments, and both refresh more often than the quarterly pathway slides need. LAAD becomes the clear candidate to replace.
  • Parallel run. Compass Prescriber is loaded beside Xponent for one quarter. National volume differs by 3 percent, but 9 of 40 territories move by more than 10 percent, enough to change payouts. Switching the crediting source mid-year is ruled out.
  • Outcome. The company keeps Xponent and OneKey on a shorter term, negotiated with the parallel-run results on the table, and moves patient-level work to the alternative that scored best on its indication.

The licences were not the biggest line in this project. The biggest was building the warehouse layer that holds both vendors' data on shared product, HCP and territory definitions, which we describe in our guide to the pharma commercial data warehouse. Without that layer, every brand review would have opened with an argument about whose number was right.

Common mistakes, and when to stay with IQVIA

  • Comparing headline coverage

    Hundreds of millions of patients or millions of HCPs says nothing about your indication. Only a feasibility count on your own market definition does.

  • Switching incentive data mid-year

    Changing the crediting source inside a plan year breaks goal comparisons and invites disputes. Switch at a plan boundary after a parallel run, or not at all.

  • Forgetting the identifier remap

    A new reference data key touches CRM, alignment, segmentation and every warehouse join. Scope it before you sign, not after the first broken report.

  • Buying AI before the data question

    Every vendor now sells AI on top; IQVIA's own Q3 2026 release cites over 400 AI agents deployed. Pick the data that answers your top three questions first, then judge the tools on it.

  • Stay if you need global data

    If forecasting, launch sequencing or market sizing covers several countries, IQVIA is still the vendor with data in most of them. Replace US components selectively instead.

  • Stay if the move costs more than it saves

    If the parallel run shows large territory shifts and your contract savings are small, renew on better terms and revisit at the next plan boundary.

How Greenwolf helps with an IQVIA decision

We do not resell IQVIA, Veeva, Komodo, HealthVerity or any other data provider and we are not paid by them, so our only interest is that the data fits your questions and your systems. Our founder came up through pharma commercial operations consulting at ZS, and our pharma commercial analytics practice builds the layer between licensed data and the people who use it.

On a renewal we inventory what you license and who depends on it, write the market definition, run feasibility and parallel tests across IQVIA and the alternatives, score the results and price the full move, including identifiers and incentive compensation. After you decide, we build the pipelines, crosswalks and dashboards on agreed definitions. For a specialty therapy provider whose identifiers did not line up across sources, clean identifiers and automated pipelines cut manual reporting work by 60 to 80 percent. If you are weighing whether to keep analytics in-house or outsource it, our guide to pharma commercial analytics outsourcing covers that decision. All of it sits within our wider specialty pharmacy analytics practice.

Questions about IQVIA alternatives

Who are IQVIA's main competitors?
It depends on the business line. In commercial data the main competitors are Veeva (Compass and OpenData), Komodo Health, HealthVerity with Symphony Health, H1 and Definitive Healthcare. In clinical research they are other CROs such as ICON, Parexel and Medpace, which are not alternatives for commercial data.
What is the best alternative to IQVIA Xponent?
Veeva Compass Prescriber and Symphony Health PrescriberSource are the two prescriber-level prescription data products built to compete with Xponent. Compass counts retail and non-retail volume in one view; Symphony now sits inside HealthVerity alongside linked claims and EMR data. Test both on your own market before deciding.
Is there an alternative to IQVIA OneKey?
Veeva OpenData is the direct alternative, with US coverage of 12 million HCPs and 2 million HCOs on Veeva's own figures against OneKey's 11.3 million HCPs and 746,211 HCOs. The vendors count organisations differently, so compare match rates on your own target accounts rather than the totals.
Can I use IQVIA data in Veeva software?
Yes. Under the third-party access agreements signed when IQVIA and Veeva settled on 18 August 2025, customers can use IQVIA data in Veeva Network, Veeva Nitro and Veeva AI, and Veeva data in IQVIA software. Agencies and consultants who touch IQVIA data still work under IQVIA's access terms.
How much does IQVIA data cost compared with alternatives?
None of the major vendors publishes list prices, so any figure you see online is a guess. Cost depends on products, brands, history, refresh, seats and term. Compare the full cost of a move, including identifier remapping, parallel running and analyst time, not just the licence quotes.
Does a small biotech need IQVIA at all?
Not always. Before launch, a one-off feasibility study can answer sizing questions. After launch, a brand moving through a limited specialty pharmacy network can answer most operational questions from its own pharmacy and hub data, adding prescriber-level Rx data once a field team's pay depends on it.
How long does it take to switch from IQVIA to another data vendor?
Plan for at least one full quarter of parallel running before switching any source used for incentive compensation, and time the switch to a plan year boundary. Patient-level data used for analysis rather than pay can move faster, once the new feed is loaded and its definitions are agreed.

Facing an IQVIA renewal or a first data purchase?

Tell us what you license today, which teams depend on it and what you want to change. We will outline a feasibility and parallel test across IQVIA and the alternatives, and what the full move would cost. Please do not send any patient information.

Contact us

Reviewed by Team Greenwolf Tech Labs ยท

Part of our Pharma Commercial and Patient Analytics hub. Start with our specialty pharmacy analytics.

Talk to us

Is this a problem you are living with?

If any of the above sounds like your week, tell us which part. We will come back with what it would take to fix it.

  • A reply from a consultant, not a sales sequence
  • Usually within one working day
  • No obligation, and nothing to sit through

We reply from [email protected], usually within one working day. We do not add you to a mailing list.